ImmunoPrecise Antibodies Announces Groundbreaking AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation Studies

Reuters

2025/06/12

ImmunoPrecise Antibodies Announces Groundbreaking AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation Studies

ImmunoPrecise Antibodies Ltd. Announces AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation ImmunoPrecise Antibodies Ltd. $(IPA)$ has announced new in vitro results for its AI-designed GLP-1 receptor agonist peptides, which have shown comparable or superior receptor activation to Semaglutide, a leading GLP-1 therapy. The analysis, conducted by an independent third party, highlights the potential of AI in generating functionally validated peptide drugs. The company is exploring two preclinical paths for its GLP-1 candidates: injectable delivery studies and non-invasive delivery strategies, such as transdermal patches and nucleic acid-based delivery systems. These developments align with ImmunoPrecise's goals of enhancing therapeutic durability, patient compliance, and ease of administration. The results, demonstrating the efficacy of the HYFT-driven design approach, have already been presented, marking a significant step in AI-powered drug discovery with applications extending to other therapeutic areas.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250612568013) on June 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542519940"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542519940\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542519940?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-12 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542519940","market":"nz","top_or_hot":-1,"title":"ImmunoPrecise Antibodies Announces Groundbreaking AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation Studies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Announces Groundbreaking AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. Announces AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation ImmunoPrecise Antibodies Ltd. <a href=\"https://laohu8.com/S/IPA\">$(IPA)$</a> has announced new in vitro results for its AI-designed GLP-1 receptor agonist peptides, which have shown comparable or superior receptor activation to Semaglutide, a leading GLP-1 therapy. The analysis, conducted by an independent third party, highlights the potential of AI in generating functionally validated peptide drugs. The company is exploring two preclinical paths for its GLP-1 candidates: injectable delivery studies and non-invasive delivery strategies, such as transdermal patches and nucleic acid-based delivery systems. These developments align with ImmunoPrecise's goals of enhancing therapeutic durability, patient compliance, and ease of administration. The results, demonstrating the efficacy of the HYFT-driven design approach, have already been presented, marking a significant step in AI-powered drug discovery with applications extending to other therapeutic areas.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250612568013) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunoPrecise Antibodies Announces Groundbreaking AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoPrecise Antibodies Announces Groundbreaking AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation Studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-12 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Announces Groundbreaking AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. Announces AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation ImmunoPrecise Antibodies Ltd. <a href=\"https://laohu8.com/S/IPA\">$(IPA)$</a> has announced new in vitro results for its AI-designed GLP-1 receptor agonist peptides, which have shown comparable or superior receptor activation to Semaglutide, a leading GLP-1 therapy. The analysis, conducted by an independent third party, highlights the potential of AI in generating functionally validated peptide drugs. The company is exploring two preclinical paths for its GLP-1 candidates: injectable delivery studies and non-invasive delivery strategies, such as transdermal patches and nucleic acid-based delivery systems. These developments align with ImmunoPrecise's goals of enhancing therapeutic durability, patient compliance, and ease of administration. The results, demonstrating the efficacy of the HYFT-driven design approach, have already been presented, marking a significant step in AI-powered drug discovery with applications extending to other therapeutic areas.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250612568013) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL1KC90n:1","article_id":"2542519940","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542519940","pubTimestamp":1749729719,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunoPrecise Antibodies Announces Groundbreaking AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation Studies. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire  on June 12, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务"},"translate_title":"ImmunoPrecise Antibodies宣布突破性人工智能设计的GLP-1肽在受体激活研究中超越索马鲁肽","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"ImmunoPrecise Antibodies Announces Groundbreaking AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation Studies\n    \n\n        ImmunoPrecise Antibodies Ltd. Announces AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation ImmunoPrecise Antibodies Ltd. $(IPA)$ has announced new in vitro results for its AI-designed GLP-1 receptor agonist peptides, which have shown comparable or superior receptor activation to Semaglutide, a leading GLP-1 therapy. The analysis, conducted by an independent third party, highlights the potential of AI in generating functionally validated peptide drugs. The company is exploring two preclinical paths for its GLP-1 candidates: injectable delivery studies and non-invasive delivery strategies, such as transdermal patches and nucleic acid-based delivery systems. These developments align with ImmunoPrecise's goals of enhancing therapeutic durability, patient compliance, and ease of administration. The results, demonstrating the efficacy of the HYFT-driven design approach, have already been presented, marking a significant step in AI-powered drug discovery with applications extending to other therapeutic areas.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250612568013) on June 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}